Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · Oct 2008
Review Meta AnalysisInterval debulking surgery for advanced epithelial ovarian cancer.
Primary debulking surgery, a crucial step in the management of epithelial ovarian cancer, is not always possible in patients with advanced stage disease (stage III to IV). In some circumstances, surgery may have been attempted but generally does not yield good results with residual tumour masses > 1 to 2 cm (so called suboptimal surgery). Induction or neoadjuvant chemotherapy followed by interval debulking surgery (IDS) may have an alternative role in this setting. However, the advantage of IDS compared to conventional methods is still a controversial issue. ⋯ No conclusive evidence was found to determine whether IDS between cycles of chemotherapy would improve or decrease the survival of women with advanced ovarian cancer, compared with conventional treatment of primary surgery followed by adjuvant chemotherapy. IDS appeared to yield benefit only in the patients whose primary surgery was not performed by gynecologic oncologists. Data on QOL and adverse events were inconclusive.
-
Cochrane Db Syst Rev · Oct 2008
Review Meta AnalysisFluticasone at different doses for chronic asthma in adults and children.
Inhaled fluticasone propionate (FP) is a high-potency inhaled corticosteroid used in the treatment of asthma. ⋯ We have not found evidence of a pronounced dose response in FEV1 with increasing doses of fluticasone. The number of studies contributing to our primary outcomes was low. At dose ratios of 1:2, there are statistically significant differences in favour of the higher dose in morning peak flow across the low dose range. The clinical impact of these differences is open to interpretation. Patients with moderate disease achieve similar levels of asthma control on medium doses of fluticasone (400 to 500 microg/day) as they do on high doses (800 to 1000 microg/day). More work in severe asthma would help to confirm that doses of FP above 500 microg/day confer greater benefit in this subgroup than doses of around 200 microg/day. In oral corticosteroid-dependent asthmatics, reductions in prednisolone requirement may be gained with FP 2000 microg/day.
-
Cochrane Db Syst Rev · Oct 2008
Review Meta AnalysisDrugs for treating uncomplicated malaria in pregnant women.
Women are more vulnerable to malaria during pregnancy, and malaria infection may have adverse consequences for the fetus. Identifying safe and effective treatments is important. ⋯ Data are scant. Some combination treatments appear to be effective at treating malaria in pregnancy; however, safety data are limited.
-
Cochrane Db Syst Rev · Oct 2008
Review Meta AnalysisDifferent corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth.
Despite the widespread use of antenatal corticosteroids to prevent respiratory distress syndrome in preterm infants, there is currently no consensus as to the type of corticosteroid to use; nor the dose, frequency or timing of use or the route of administration. ⋯ Dexamethasone may have some benefits compared with betamethasone such as less intraventricular haemorrhage, although perhaps a higher rate of NICU admission (seen in only one trial). Apart from a suggestion from another small trial that the intramuscular route may have advantages over an oral route for dexamethasone, few other conclusions about optimal antenatal corticosteroid regimens were able to be made. Trials of commonly used corticosteroids are most urgently needed, followed by trials of dosages and other variations in regimens.
-
Cochrane Db Syst Rev · Oct 2008
Review Meta AnalysisInhaled sodium cromoglycate for asthma in children.
Sodium cromoglycate has been recommended as maintenance treatment for childhood asthma for many years. Its use has decreased since 1990, when inhaled corticosteroids became popular, but it is still used in many countries. ⋯ There is insufficient evidence to be sure about the efficacy of sodium cromoglycate over placebo. Publication bias is likely to have overestimated the beneficial effects of sodium cromoglycate as maintenance therapy in childhood asthma.